Latest Industry Insights

In bioanalysis, AI could alleviate preclinical and clinical bioanalytical data processing and analysis. Here, Mary Belfast from Teva Branded Pharmaceuticals, discusses some of the latest guidelines on AI implementation and validation in bioanalysis.

We sat down with Professor Peter Van Eenoo, director of the Doping Control Laboratory (DoCoLab), part of the University of Ghent, Belgium, to discuss the intricacies of anti-doping testing and the challenges faced in catching sporting cheats.

In this interview, Tola Olorunnisola, senior vice president and general manager at Avantor, delves into how AI and automation could put the Lab of the Future within our grasp, enabling scientific breakthroughs and revolutionizing the drug development process.

Elsevier’s “Insights 2024: Attitudes toward AI” report reveals how researchers feel about AI and what is needed to increase trust in these tools. Here, Mirit Eldor, managing director, life sciences at Elsevier discusses these findings further.

Western blotting is a staple technique in many laboratories but can be time consuming and inconsistent. Technology Networks spoke with Harsha Rao to learn more about Stain-Free western blotting and the advantages of total protein normalization.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Tim Dillon, market manager (Nordics) at Mettler-Toledo Rainin, to learn about how more sustainable options can be implemented into scientists’ daily workflows.

Dr. Omid Farokhzad, chair and CEO at Seer, discusses how to achieve deep, unbiased and scalable analysis of the proteome at speed at ASMS 2024.

We spoke with Dr. Christian Dillon to learn more about degradation-based therapies, the challenges associated with their discovery and how innovative solutions are helping to realize the potential of this promising class of therapeutics.

Both genetic and epigenetic sample information is required to get the full picture. Six-base genome sequencing enables this without need of multiple techniques, laborious downstream data processing or data loss, and cancer research is benefiting.

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development. The three teams will combine data, software and tuned models to develop custom, purpose-built solutions for drug discovery.